Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders: Evaluation by in vitro probe acylcarnitine assay

► Bezafibrate decreased acylcarnitines in several FAO disorders in vitro. ► Bezafibrate improved abnormalities in a child with glutaric acidemia type 2. ► Bezafibrate is a promising treatment option for FAO disorders. ► In vitro probe assay can evaluate the effect of drugs to treat FAO disorders.